🌍·15h agodiscovery
IDEAYA Biosciences Doses First Patient in Phase 3 Trial
Publisher
g
grafa.com
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- grafa.com
- Region
- Global
- Scope
- discovery
- Published
- September 9, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: grafa.com
Scope: discovery
Related coverage
More related coverage
Crossref/5h ago
Short-Term Efficacy of Tegoprazan Compared With Esomeprazole in Patients With Non-Erosive Reflux Disease and Nocturnal Heartburn Symptoms: A Double-Blind, Randomized Controlled Trial
Crossref/5h ago
Proposals for Individually Safe and Realistic Correction of Antipsychotics in Hospitalized Patients with Schizophrenia: A Prescription Survey at Nagoya University Hospital
Crossref/5h ago
Development of a Rubric for Assessing Essential “Basic Social Skills” Required at the Time of Employment and Its Evaluation in Clinical Training
Crossref/5h ago